Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a r... per Jie Ju, Song‐Lin Gao, Jia‐Yu Wang, Die Sang, Yi‐Kun Kang, Xue Wang, Jian Yue, You Shuai, Yi‐Xin Qi, Peng Yuan

Obtenir text complet